DE602004015418D1 - Rekombinantes mva und verfahren zur erzeugung davon - Google Patents

Rekombinantes mva und verfahren zur erzeugung davon

Info

Publication number
DE602004015418D1
DE602004015418D1 DE200460015418 DE602004015418T DE602004015418D1 DE 602004015418 D1 DE602004015418 D1 DE 602004015418D1 DE 200460015418 DE200460015418 DE 200460015418 DE 602004015418 T DE602004015418 T DE 602004015418T DE 602004015418 D1 DE602004015418 D1 DE 602004015418D1
Authority
DE
Germany
Prior art keywords
recombinant mva
mva
production
dna
generation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE200460015418
Other languages
English (en)
Inventor
Caroline Staib
Marianne Loewel
Volker Erfle
Gerd Sutter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Publication of DE602004015418D1 publication Critical patent/DE602004015418D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A61K39/285—Vaccinia virus or variola virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE200460015418 2003-02-18 2004-02-18 Rekombinantes mva und verfahren zur erzeugung davon Expired - Lifetime DE602004015418D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44823103P 2003-02-18 2003-02-18
PCT/EP2004/001554 WO2004074493A1 (en) 2003-02-18 2004-02-18 Recombinant mva and method for generation thereof

Publications (1)

Publication Number Publication Date
DE602004015418D1 true DE602004015418D1 (de) 2008-09-11

Family

ID=32908561

Family Applications (1)

Application Number Title Priority Date Filing Date
DE200460015418 Expired - Lifetime DE602004015418D1 (de) 2003-02-18 2004-02-18 Rekombinantes mva und verfahren zur erzeugung davon

Country Status (8)

Country Link
US (1) US20060002896A1 (de)
EP (1) EP1594970B1 (de)
JP (2) JP4686443B2 (de)
CN (1) CN1723285B (de)
AT (1) ATE403005T1 (de)
DE (1) DE602004015418D1 (de)
DK (1) DK1594970T3 (de)
WO (1) WO2004074493A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
CA2511625A1 (en) 2002-12-23 2004-07-15 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
EP2199400A1 (de) 2008-12-22 2010-06-23 Emergent Product Development Germany GmbH System und Verwendungsverfahren für die einzelne Rekombination
CN102559611B (zh) * 2011-06-23 2015-04-22 江苏省农业科学院 一种无筛选标记的双表达重组mva病毒及其构建方法
JP7034080B2 (ja) * 2016-02-25 2022-03-11 メモリアル スローン ケタリング キャンサー センター ヒトｆｌｔ３ｌを発現する組換えｍｖａまたはｍｖａδｅ３ｌおよび固形腫瘍に対する免疫療法薬としてのそれらの使用
KR20190050787A (ko) * 2016-08-19 2019-05-13 세멘티스 리미티드 바이러스 백신
EP3928789A1 (de) 2020-06-24 2021-12-29 Consejo Superior de Investigaciones Científicas (CSIC) Mva-basierter impfstoff gegen covid-19 exprimierende sars-cov-2-antigene
WO2021260065A1 (en) 2020-06-24 2021-12-30 Consejo Superior De Investigaciones Científicas (Csic) Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
EP4108257A1 (de) 2021-06-23 2022-12-28 Consejo Superior De Investigaciones Científicas Impfstoff auf mva-basis gegen covid-19, der ein präfusionsstabilisiertes sars-cov-2-s-protein exprimiert
WO2022269003A1 (en) 2021-06-23 2022-12-29 Consejo Superior De Investigaciones Cientificas MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN
EP4316514A1 (de) 2022-08-03 2024-02-07 Consejo Superior de Investigaciones Científicas (CSIC) Vektoren auf mva-basis und ihre verwendung als impfstoff gegen sars-cov-2

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100242671B1 (ko) * 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
WO1998037095A2 (en) * 1997-02-24 1998-08-27 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
CA2409874A1 (en) * 2000-05-24 2001-11-29 Merial Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
GB0111442D0 (en) * 2001-05-10 2001-07-04 Isis Innovation Method for preparing recombinant virus

Also Published As

Publication number Publication date
EP1594970A1 (de) 2005-11-16
CN1723285A (zh) 2006-01-18
JP2006517795A (ja) 2006-08-03
WO2004074493A1 (en) 2004-09-02
CN1723285B (zh) 2013-01-02
EP1594970B1 (de) 2008-07-30
DK1594970T3 (da) 2008-11-17
JP5166505B2 (ja) 2013-03-21
US20060002896A1 (en) 2006-01-05
JP4686443B2 (ja) 2011-05-25
JP2011055840A (ja) 2011-03-24
ATE403005T1 (de) 2008-08-15

Similar Documents

Publication Publication Date Title
WO2019126634A3 (en) Targeted integration of nucleic acids
CY1118222T1 (el) Συνθεσεις λυασης φαινυλαλανινης αμμωνιας προκαρυωτικων και μεθοδοι αγωγης καρκινου χρησιμοποιωντας συνθεσεις εξ' αυτης
ATE476196T1 (de) Zusammensetzung zur auslösung, verbesserung und erhaltung von immunantworten gegen mhc-klasse-i- beschränkte epitope, für prophylaktische oder therapeutische zwecke
MX2009001203A (es) Muteinas de lipocalina lacrimosa y metodos para obtener las mismas.
BRPI0519766A2 (pt) proteases Ácidas féngicas
ATE501264T1 (de) Enzymatische verfahren zur herstellung 4- substituierter 3-hydroxybuttersäure-derivate
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
MY139896A (en) Improved prrs vaccines
DE602004015418D1 (de) Rekombinantes mva und verfahren zur erzeugung davon
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
EA201171481A1 (ru) Способ получения высококонцентрированного препарата иммуноглобулина для подкожного применения
BR112013032434A2 (pt) restauração dentária, método para sua produção e vidro cerâmico
ATE526403T1 (de) L-threonin-überproduktions-mikroorganismus und verfahren zur herstellung von l-threonin damit
DE60224843D1 (de) Herstellung von viren, virusisolaten, und impfstoffen
ATE500327T1 (de) Verfahren und zusammensetzungen für ethanolproduzierende cyanobakterien
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
ATE529409T1 (de) Verfahren zur herstellung von kristallinen aripiprazolformen
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
MX2011013117A (es) Peptidos especificos del receptor de melanocortina.
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
ATE367167T1 (de) Aufbereitung von aldesleukin zur pharmazeutischen verwendung
ATE393775T1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
DE60227268D1 (de) Knockout-mutante von vaccinia-virus und verwendung davon
WO2008033556A3 (en) High pressure treatment of proteins for reduced immunogenicity
ATE526034T1 (de) Verbesserte inaktivierte fcv-vakzinen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition